Summary of opinion: mResvia, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Summary of opinion: mResvia, 26/03/2026 Positive
Reflection paper on a tailored clinical approach in biosimilar development
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Reflection paper on a tailored clinical approach in biosimilar development
Biosimilar medicines: Overview
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Biosimilar medicines: Overview
Type-IA variations: questions and answers
Submitted by Anonymous (not verified) on 27 March 2026 - 12:00
Type-IA variations: questions and answers
Summary of opinion: Retsevmo, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 11:46
Summary of opinion: Retsevmo, 26/03/2026 Positive
Summary of opinion: Hetronifly, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 11:45
Summary of opinion: Hetronifly, 26/03/2026 Positive
Summary of opinion: Capvaxive, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 11:44
Summary of opinion: Capvaxive, 26/03/2026 Positive
Summary of opinion: Feraccru, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 11:43
Summary of opinion: Feraccru, 26/03/2026 Positive
Summary of opinion: Besponsa, 26/03/2026 Positive
Submitted by Anonymous (not verified) on 27 March 2026 - 11:43
Summary of opinion: Besponsa, 26/03/2026 Positive
Human medicines European public assessment report (EPAR): Bopediat, furosemide, Status: Opinion
Submitted by Anonymous (not verified) on 27 March 2026 - 11:41
Human medicines European public assessment report (EPAR): Bopediat, furosemide, Status: Opinion